论文部分内容阅读
该文总结了７１例胃癌手术辅以化疗的临床效果。将患者随机分成两组：试验组３７例进展期胃癌除行胃癌根治术外，辅以术前５－Ｆｕ静脉滴注、复方氟脲嘧啶胃内灌注，术中癌肿周围、腹腔动脉旁、肠系膜根部５－Ｆｕ封闭，遗留的小淋巴结内５－Ｆｕ注射和腹腔内温热低渗５－Ｆｕ灌洗，对照组３４例进展期胃癌行胃癌根治术后５－Ｆｕ常规化疗。结果显示１０年随访中试验组患者３年和５年生存率分别为６２．４２％和５１．５６％，而对照组为４８．０３％和３２．３３％，两者差异有显著性（Ｐ＜０．０５）。ＴＮＭ分期Ⅲａ期病人试验组３年和５年生存率分别为６７．３１％和５８．９０％，而对照组为４４．８８％和２８．５６％，两者差异有显著性（Ｐ＜０．０５）。故胃癌手术一次多途径术前及术中化疗具有提高胃癌根治术疗效和降低化疗药物毒副作用的重要作用，值得推广应用。
This paper summarizes the clinical effects of 71 cases of gastric cancer assisted by chemotherapy. The patients were randomly divided into two groups: the experimental group of 37 patients with advanced gastric cancer in addition to gastric cancer radical surgery, supplemented with preoperative 5-Fu intravenous infusion, compound 5-fluorouracil intragastric perfusion, intraoperative cancer around the celiac artery, The mesenteric roots were closed with 5-Fu, the remaining small lymph nodes were injected with 5-Fu and the intraperitoneal warm hypoosmotic 5-Fu was lavaged. The control group consisted of 34 patients with advanced gastric cancer who underwent 5-Fu chemotherapy after radical gastrectomy. The results showed that the 3-year and 5-year survival rates of the experimental group at the 10-year follow-up were 62.42% and 51.56%, respectively, while those in the control group were 48.03% and 32.33%. The difference between the two groups was significant (P <0.05). The three-year and five-year survival rates of TNM stage IIIa patients were 67.31% and 58.90%, respectively, while those in the control group were 44.88% and 28.56%. There was a significant difference between the two groups (P<0). .05). Therefore, multiple routes of gastric cancer surgery and preoperative and intraoperative chemotherapy have an important role in improving the efficacy of gastric cancer radical surgery and reduce the toxic side effects of chemotherapy drugs, it is worth promoting.